Full synthesis of halichondrin molecule could be key in search for cancer cure
Japanese scientists first sourced halichondrin from sea sponges in 1986, and have been attempting to manufacture it for…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
13 Nov 19
Japanese scientists first sourced halichondrin from sea sponges in 1986, and have been attempting to manufacture it for…
13 Nov 19
The EMPULSE study is a multi-centre, randomised, double-blind study to assess the oral EMPagliflozin 10mg compared to placebo
12 Nov 19
The transaction is expected to be completed in the first half of 2020, subject to fulfilment of certain…
11 Nov 19
Gazyva is a monoclonal antibody designed to attach to CD20, a protein that can be observed only on…
11 Nov 19
The BELIEVE trial has reached both primary and secondary end points and REBLOZYL has demonstrated reduced RBC transfusion…
08 Nov 19
INXN-4001 makes use of non-viral delivery of a constitutively expressed multigenic plasmid to express human S100A1, SDF-1α, and…
08 Nov 19
Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) indicated to promote erythropoiesis by increasing endogenous production of…
06 Nov 19
Ziextenzo is approved for treating patients with non-myeloid malignancies, under myelosuppressive anti-cancer drugs, and with an incidence of…
04 Nov 19
The results from EXCEED demonstrated a consistent and favourable safety profile for Cosentyx and no new safety signals…
01 Nov 19
BeiGene will commercialise Amgen’s Xgeva, Kyprolis and Blincyto in China for five or seven years, for equal share…